Psikedelik Destekli Terapiler: Bir Gözden Geçirme

Öz

Psikedelikler, yarım asır süren yasaklamaların ve bilimsel yok sayılmanın ardından, modern psikiyatride potansiyel bir paradigma kaymasının habercisi olarak yeniden ortaya çıkmaktadır. Bu derleme, psikedelik destekli psikoterapinin (PDP) tarihsel kökenlerini, sosyopolitik engellerini ve günümüzdeki bilimsel rönesansını bütüncül bir bakış açısıyla ele almaktadır. Çalışma kapsamında, temel moleküllerin (Psilosibin, LSD, MDMA, Ketamin, DMT, Ibogain, Meskalin) farmakolojik profilleri, standardize edilmiş terapi protokolleri, klinik etkinlikleri ve güvenlik profilleri karşılaştırmalı olarak incelenmektedir. Farklı kimyasal sınıflara ait olmalarına rağmen, bu maddelerin çoğunun Varsayılan Mod Ağı (DMN) inhibisyonu ve nöroplastisiteyi teşvik etme gibi ortak nörobiyolojik yollar üzerinden bilişsel esneklik ve terapötik değişim için bir "fırsat penceresi" yarattığı gösterilmektedir. Klinik kanıtlar; MDMA'nın Travma Sonrası Stres Bozukluğu (TSSB), psilosibin ve ketaminin tedaviye dirençli depresyon (TDD), ibogainin ise opioid bağımlılığı tedavisinde umut verici olduğunu ortaya koymaktadır. Terapötik başarı, bu güçlü moleküllerin yapılandırılmış bir psikoterapi protokolü (hazırlık, seans, entegrasyon) içinde uygulanmasına sıkı sıkıya bağlıdır. Moleküle göre ciddi farklılıklar gösteren güvenlik profilleri, metodolojik sınırlılıklar (körleme zorluğu) ve sosyopolitik engeller alanın önündeki önemli zorluklardır. Sonuç olarak, psikedelik destekli psikoterapi, kronik semptom yönetimi yerine kısa süreli ve dönüştürücü müdahaleler sunarak modern psikiyatride devrim yaratma potansiyeli taşımaktadır; ancak bu potansiyelin güvenle hayata geçirilmesi, daha fazla bilimsel araştırmaya, standartlaştırılmış eğitime ve dikkatli regülasyonlara bağlıdır.

Anahtar Kelimeler

• psikedelik destekli psikoterapi
• ketamin
• depresyon

Psychedelic-Assisted Therapies: A Review

Öz

Following decades of prohibition and scientific neglect, psychedelics are re-emerging as potential harbingers of a paradigm shift in modern psychiatry. This comprehensive review examines the historical roots of psychedelic-assisted psychotherapy (PAP), the pharmacological profiles of key molecules (Psilocybin, LSD, MDMA, Ketamine, DMT, Ibogaine, Mescaline), their standardized therapeutic protocols, clinical efficacy, and safety profiles. Despite belonging to diverse chemical classes, it is shown that most of these substances converge on common neurobiological pathways, such as inhibition of the Default Mode Network (DMN) and promotion of neuroplasticity, creating a "window of opportunity" for cognitive flexibility and therapeutic change. Clinical evidence indicates significant promise for MDMA in treating Post-Traumatic Stress Disorder (PTSD), psilocybin and ketamine for Treatment-Resistant Depression (TRD), and ibogaine for opioid use disorder. Therapeutic success is critically dependent on administering these potent molecules within a structured psychotherapeutic protocol (preparation, session, integration). While safety profiles differ significantly depending on the molecule (e.g., the cardiotoxicity of ibogaine, the abuse potential of ketamine), methodological limitations (e.g., challenges in blinding) and socio-political hurdles remain important challenges for the field. In conclusion, psychedelic-assisted psychotherapy holds the potential to revolutionize modern psychiatry by offering short-term, transformative interventions as an alternative to chronic symptom management. However, the safe and effective realization of this potential depends on further rigorous scientific research, standardized training, and thoughtful regulation.

Anahtar Kelimeler

• psychedelic assisted therapy
• ketamin
• depression

Kaynakça

1. Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155–166. https://doi.org/10.1177/0269881119897615
2. Albaugh, B. J., & Anderson, P. O. (1974). Peyote in the treatment of alcoholism among American Indians. American Journal of Psychiatry, 131(1), 45–50. https://doi.org/10.1176/ajp.131.11.1247
3. Alper, K. R., Stajic, M., & Gill, J. R. (2012). Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Sciences, 57(2), 398–412. https://doi.org/10.1111/j.1556-4029.2011.02008.x
4. Anderson, B. T., Danforth, A., Daroff, P. R., Stauffer, C., Ekman, E., Agin-Liebes, G., Trope, A., Boden, M. T., Dilley, P. J., Mitchell, J., & Woolley, J. (2020). Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. eClinicalMedicine, 27, 100538. https://doi.org/10.1016/j.eclinm.2020.100538
5. Andersson, M., Persson, M., & Kjellgren, A. (2017). Psychoactive substances as a last resort—A qualitative study of self-treatment of migraine and cluster headaches. Harm Reduction Journal, 14(1), 2. https://doi.org/10.1186/s12954-017-0186-6
6. Appiani, F. J., & Caroff, S. N. (2024). The cyclical revival of psychedelics in psychiatric treatment. Current Medical Research and Opinion, 40(8), 1389–1396. https://doi.org/10.1080/03007995.2024.2368725
7. Belouin, S. J., & Henningfield, J. E. (2018). Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology, 142, 7–19. https://doi.org/10.1016/j.neuropharm.2018.02.018
8. Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299. https://doi.org/10.1177/0269881114565144

9. Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., Rotrosen, J., Tonigan, J. S., & Worth, L. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 79(10), 953–962. https://doi.org/10.1001/jamapsychiatry.2022.2096
10. Borgogna, N. C., Owen, T., Petrovitch, D., Vaughn, J., Johnson, D. A. L., Pagano, L. A., Aita, S. L., & Hill, B. D. (2025). Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. Psychopharmacology. Advance online publication. https://doi.org/10.1007/s00213-025-06788-w
11. Brown, T. K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes. American Journal of Drug and Alcohol Abuse, 44(1), 24–36. https://doi.org/10.1080/00952990.2017.1320802
12. Butler, M., Jelen, L., & Rucker, J. (2022). Expectancy in placebo-controlled trials of psychedelics: If so, so what? Psychopharmacology, 239(10), 3047–3055. https://doi.org/10.1007/s00213-022-06221-6
13. C. Mash, D. (2018). Breaking the cycle of opioid use disorder with ibogaine. American Journal of Drug and Alcohol Abuse, 44(1), 1–3. https://doi.org/10.1080/00952990.2017.1357184
14. Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., & Drevets, W. C. (2020). Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: A randomized, double-blind, placebo-controlled trial. Scientific Reports, 10(1), 75706. https://doi.org/10.1038/s41598-020-75706-1
15. Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 1268–1278. https://doi.org/10.1177/0269881116662634
16. Carhart-Harris, R. L. (2019). How do psychedelics work? Current Opinion in Psychiatry, 32(1), 16–21. https://doi.org/10.1097/YCO.0000000000000467
17. Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994
18. Carhart-Harris, R. L., Erritzoe, D., Haijen, E., Kaelen, M., & Watts, R. (2018). Psychedelics and connectedness. Psychopharmacology, 235(2), 547–550. https://doi.org/10.1007/s00213-017-4701-y
19. Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285
20. Dinis-Oliveira, R. J. (2017). Metabolism of psilocybin and psilocin: Clinical and forensic toxicological relevance. Drug Metabolism Reviews, 49(1), 84–91. https://doi.org/10.1080/03602532.2016.1278228
21. dos Santos, R. G., Bouso, J. C., Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2021). Hallucinogens in mental health: Preclinical and clinical studies on LSD, psilocybin, MDMA, and DMT. Journal of Neuroscience, 41(5), 733–740. https://doi.org/10.1523/JNEUROSCI.1658-20.2020
22. dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016). Antidepressant effects of a single dose of ayahuasca in patients with major depression. Journal of Clinical Psychopharmacology, 36(1), 77–81. https://doi.org/10.1097/JCP.0000000000000436
23. Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., Aan Het Rot, M., Lapidus, K. A. B., Wan, L. Ben, Iosifescu, D., & Charney, D. S. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry, 71(6), 681–688. https://doi.org/10.1001/jamapsychiatry.2014.62
24. Feduccia, A. A., Jerome, L., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2021). Breakthrough for trauma treatment: Safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Frontiers in Psychiatry, 12, 735904. https://doi.org/10.3389/fpsyt.2021.735904
25. Fuentes, J. J., Fonseca, F., Elices, M., Farré, M., & Torrens, M. (2020). Therapeutic use of LSD in psychiatry: A systematic review of randomized-controlled clinical trials. Journal of Clinical Psychiatry, 81(1), 19r12956. https://doi.org/10.4088/JCP.19r12956
26. Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews, 7(3), 157–164. https://doi.org/10.2174/1874473708666150107121331
27. Gattuso, J. J., Perkins, D., Ruffell, S., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L. A., Pagni, B. A., Galvão-Coelho, N. L., Nutt, D., & Sarris, J. (2023). Default mode network modulation by psychedelics: A systematic review. International Journal of Neuropsychopharmacology, 26(3), 155–188. https://doi.org/10.1093/ijnp/pyac074
28. Glue, P., Neehoff, S., Sabadel, A., Broughton, L., Le Nedelec, M., Shadli, S., McNaughton, N., & Medlicott, N. J. (2020). Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. Journal of Psychopharmacology, 34(3), 267–272. https://doi.org/10.1177/0269881119874457
29. Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. Psychopharmacology, 233(21), 513–520. https://doi.org/10.1007/s00213-016-4372-8
30. Grunebaum, M. F., Galfalvy, H. C., Choo, T. H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., Oquendo, M. A., & Mann, J. J. (2018). Ketamine for rapid reduction of suicidal thoughts in major depression: A midazolam-controlled randomized clinical trial. American Journal of Psychiatry, 175(4), 327–335. https://doi.org/10.1176/appi.ajp.2017.17060647
31. Halberstadt, A. L., & Geyer, M. A. (2018). Effect of hallucinogens on unconditioned behavior. Current Topics in Behavioral Neurosciences, 36, 159–199. https://doi.org/10.1007/7854_2016_466
32. Hall, W. (2022). Why was early therapeutic research on psychedelic drugs abandoned? Psychological Medicine, 52(1), 26–31. https://doi.org/10.1017/S0033291721004207
33. Halpern, J. H., & Pope, H. G. (2003). Hallucinogen persisting perception disorder: What do we know after 50 years? Drug and Alcohol Dependence, 69(2), 109–119. https://doi.org/10.1016/S0376-8716(02)00306-X
34. Henderson, I., Elsaadany, R., Chan, G., Bajaj, V., Duarte, D., Goodman, S., Grunstein, M., Vadhan, N. P., & Duarte, R. A. (2025). Exploring the potential of psychedelics in the treatment of headache disorders: Clinical considerations and exploratory insights. Current Pain and Headache Reports, 29(1), 1–14. https://doi.org/10.1007/s11916-024-01321-8
35. Hofmann, A. (1980). LSD: My problem child. McGraw-Hill.
36. Holze, F., Gasser, P., Müller, F., Dolder, P. C., & Liechti, M. E. (2022). Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: A randomized, double-blind, placebo-controlled Phase II study. Psychopharmacology, 239(6), 1857–1867. https://doi.org/10.1007/s00213-021-05991-7
37. Holze, F., Singh, N., Liechti, M. E., & D’Souza, D. C. (2024). Serotonergic psychedelics: A comparative review of efficacy, safety, pharmacokinetics, and binding profile. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 9(5), 472–489. https://doi.org/10.1016/j.bpsc.2024.01.007
38. Holze, F., Vizeli, P., Müller, F., Ley, L., Duthaler, U., Stocker, M., Kraehenmann, R., & Liechti, M. E. (2020). Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. European Neuropsychopharmacology, 40, 16–27. https://doi.org/10.1016/j.euroneuro.2020.09.638
39. Inserra, A., De Gregorio, D., & Gobbi, G. (2021). Psychedelics in psychiatry: Neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacological Reviews, 73(1), 7–15. https://doi.org/10.1124/pharmrev.120.000004
40. Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. American Journal of Drug and Alcohol Abuse, 43(1), 55–60. https://doi.org/10.3109/00952990.2016.1170135
41. Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics, 197, 83–102. https://doi.org/10.1016/j.pharmthera.2018.11.010
42. Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620. https://doi.org/10.1177/0269881108093587
43. Kaar, S., & Morgan, C. (2022). Ketamine-assisted psychological therapy to reduce alcohol relapse. International Standard Randomized Controlled Trial Number Registry. https://doi.org/10.1186/ISRCTN85955128
44. Kamal, S., Jha, M. K., & Radhakrishnan, R. (2023). Role of psychedelics in treatment-resistant depression. Psychiatric Clinics of North America, 46(2), 291–305. https://doi.org/10.1016/j.psc.2023.02.004
45. Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2023). Psychedelics, mystical experience, and therapeutic efficacy: A systematic review. Frontiers in Psychiatry, 14, 1129210. https://doi.org/10.3389/fpsyt.2023.1129210
46. Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020). Reviewing the potential of psychedelics for the treatment of PTSD. International Journal of Neuropsychopharmacology, 23(6), 385–400. https://doi.org/10.1093/ijnp/pyaa018
47. Krupitsky, E. M., Burakov, A. M., Dunaevsky, I. V., Romanova, T. N., Slavina, T. Y., & Grinenko, A. Y. (2007). Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. Journal of Psychoactive Drugs, 39(1), 13–19. https://doi.org/10.1080/02791072.2007.10399860
48. Krystal, J. H., Kaye, A. P., Jefferson, S., Murrough, J. W., & Charney, D. S. (2021). Ketamine and rapid-acting antidepressants: A new era in the battle against depression and suicide. Nature Medicine, 27(6), 1025–1033. https://doi.org/10.1038/s41591-021-01336-3
49. Lee, M. A., & Shlain, B. (1985). Acid dreams: The complete social history of LSD, the CIA, the sixties and beyond. Grove Press.
50. Ley, L., Holze, F., Arikci, D., Becker, A. M., Straumann, I., Klaiber, A., Coviello, F., Dierbach, S., Thomann, J., Duthaler, U., Luethi, D., Varghese, N., Eckert, A., & Liechti, M. E. (2023). Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology, 48(11), 1659–1667. https://doi.org/10.1038/s41386-023-01607-2
51. Li, H., Zhang, Y., Wang, G., Zhang, C., Zhang, H., & He, J. (2022). Safety and efficacy of classic psychedelics in the treatment of depression and anxiety disorders. Frontiers in Psychiatry, 13, 887463. https://doi.org/10.3389/fpsyt.2022.887463
52. Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., Duim, W. C., Dennis, M. Y., McAllister, A. K., Ori-McKenney, K. M., Gray, J. A., & Olson, D. E. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170–3182. https://doi.org/10.1016/j.celrep.2018.05.022
53. Mash, D. C., Duque, L., Page, B., & Allen-Ferdinand, K. (2018a). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes. Frontiers in Pharmacology, 9, 529. https://doi.org/10.3389/fphar.2018.00529
54. Mash, D. C., Duque, L., Page, B., & Allen-Ferdinand, K. (2018b). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes. Frontiers in Pharmacology, 9(3), 201–210. https://doi.org/10.3389/fphar.2018.00529
55. Metaxa, A. M., & Clarke, M. (2024). Efficacy of psilocybin for treating symptoms of depression: Systematic review and meta-analysis. BMJ, 385, e078084. https://doi.org/10.1136/bmj-2023-078084
56. Mion, G., & Villevieille, T. (2013). Ketamine pharmacology: An update. CNS Drugs, 27(3), 201–210. https://doi.org/10.1007/s40263-013-0049-6
57. Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G, M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., … Doblin, R. (2021a). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033. https://doi.org/10.1038/s41591-021-01336-3
58. Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G, M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., … Doblin, R. (2021b). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033. https://doi.org/10.1038/s41591-021-01336-3
59. Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019). MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology, 236(9), 2735–2745. https://doi.org/10.1007/s00213-019-05249-5
60. Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2018). 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: A randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry, 5(6), 486–497. https://doi.org/10.1016/S2215-0366(18)30135-4
61. Mohamed, W. M. Y., Hamida, S. Ben, Cassel, J. C., De Vasconcelos, A. P., & Jones, B. C. (2011). MDMA: Interactions with other psychoactive drugs. Pharmacology, Biochemistry and Behavior, 99(4), 759–774. https://doi.org/10.1016/j.pbb.2011.06.032
62. Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry, 67(11), 1735–1740. https://doi.org/10.4088/JCP.v67n1110
63. Morgan, C. J. A., Muetzelfeldt, L., & Curran, H. V. (2010). Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: A 1-year longitudinal study. Addiction, 105(1), 121–133. https://doi.org/10.1111/j.1360-0443.2009.02761.x
64. Multidisciplinary Association for Psychedelic Studies. (2017, August 2). FDA grants breakthrough therapy designation for MDMA-assisted psychotherapy for PTSD, agrees on special protocol assessment for phase 3 trials [Press release]. https://maps.org/news/media/press-release-fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy-for-ptsd-agrees-on-special-protocol-assessment-for-phase-3-trials/
65. Nichols, D. E., & Nichols, C. D. (2025). History of psychedelic drug science and molecular pharmacology. International Review of Neurobiology, 181, 3–43. https://doi.org/10.1016/bs.irn.2025.02.001
66. Nichols, D. E., & Walter, H. (2021). The history of psychedelics in psychiatry. Pharmacopsychiatry, 54(4), 151–166. https://doi.org/10.1055/a-1310-3990
67. Nutt, D., & Carhart-Harris, R. (2021). The current status of psychedelics in psychiatry. JAMA Psychiatry, 78(2), 121–122. https://doi.org/10.1001/jamapsychiatry.2020.2171
68. Nutt, D., Erritzoe, D., & Carhart-Harris, R. (2020a). Psychedelic psychiatry’s brave new world. Cell, 181(1), 24–28. https://doi.org/10.1016/j.cell.2020.03.020
69. Nutt, D., Erritzoe, D., & Carhart-Harris, R. (2020b). Psychedelic psychiatry’s brave new world. Cell, 181(1), 721–725. https://doi.org/10.1016/j.cell.2020.03.020
70. Nutt, D. J., King, L. A., & Phillips, L. D. (2010). Drug harms in the UK: A multicriteria decision analysis. Lancet, 376(9752), 1558–1565. https://doi.org/10.1016/S0140-6736(10)61462-6
71. Olivier, B., & Olivier, J. D. A. (2024). Efficacy, safety, and tolerability of psychedelics in treatment-resistant depression (TRD). Advances in Experimental Medicine and Biology, 1456, 49–66. https://doi.org/10.1007/978-981-97-4402-2_3
72. Omidian, H., Mohammadian, R., Halayem, S., Rickli, A., & Liechti, M. E. (2025). Psychedelic-assisted psychotherapy in patients with life-threatening illness: A review of clinical trials. Pharmaceuticals, 18(4), 326. https://doi.org/10.3390/ph18040326
73. Oram, M., Schenberg, E. E., & Schindler, E. A. D. (2022). Psychedelics as a potential treatment for cluster headache: A review. Cephalalgia, 42(8), 827–837. https://doi.org/10.1177/03331024221088558
74. Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Moutinho, S. A., dos Santos, R. G., & Araujo, D. B. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression. Psychological Medicine, 49(4), 655–663. https://doi.org/10.1017/S0033291718001356
75. Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The pharmacology of lysergic acid diethylamide: A review. CNS Neuroscience & Therapeutics, 14(4), 295–302. https://doi.org/10.1111/j.1755-5949.2008.00059.x
76. Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., Molero, P., Vieta, E., Bajbouj, M., Manji, H., Drevets, W. C., & Singh, J. B. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. American Journal of Psychiatry, 176(6), 428–438. https://doi.org/10.1176/appi.ajp.2019.19020172
77. Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept. Neuropsychopharmacology, 38(12), 2475–2483. https://doi.org/10.1038/npp.2013.150
78. Rucker, J., Butler, M., Hambleton, S., Bird, C., Seynaeve, M., Cheema, S., Campbell-Coker, K., Maggio, C., Dunbar, F., Lambru, G., & Matharu, M. (2024). Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: Results from an open-label phase Ib ascending dose study. Headache: The Journal of Head and Face Pain, 64(10), 1309–1317. https://doi.org/10.1111/head.14837
79. Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018a). Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology, 142, 200–218. https://doi.org/10.1016/j.neuropharm.2017.12.040
80. Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018b). Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology, 142, 200–218. https://doi.org/10.1016/j.neuropharm.2017.12.040
81. Rucker, J. J., Jelen, L. A., Flynn, S., Fothergill, K., & Young, A. H. (2022). Psychedelics in the treatment of unipolar mood disorders: A systematic review. Psychopharmacology, 239(6), 1845–1856. https://doi.org/10.1007/s00213-021-06046-9
82. Rucker, J. J., Jelen, L. A., Flynn, S., Frowde, K. D., & Young, A. H. (2016). Psychedelics in the treatment of unipolar mood disorders: A systematic review. Journal of Psychopharmacology, 30(12), 1220–1229. https://doi.org/10.1177/0269881116679368
83. Rucker, J. J., & Seth, P. (2021). Psychedelics: Old drugs, new trips. Journal of Psychopharmacology, 35(4), 316–318. https://doi.org/10.1177/02698811211003495
84. Sandison, R. A. (2016). A history of the use of psychedelics in psychiatry. History of Psychiatry, 27(1), 45–50. https://doi.org/10.1177/0957154X15624687
85. Sarris, J., Perkins, D., & Mithoefer, M. C. (2022). Psychedelic drugs: A new era in psychiatry? Dialogues in Clinical Neuroscience, 24(1), 99–105. https://doi.org/10.1080/12949688.2022.2042850
86. Schipper, S., Nigam, K., Schmid, Y., Piechotta, V., Ljuslin, M., Beaussant, Y., Schwarzer, G., & Boehlke, C. (2024). Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases. Cochrane Database of Systematic Reviews, 9(9), CD015383. https://doi.org/10.1002/14651858.CD015383.pub2
87. Schmid, Y., Gasser, P., Oehen, P., & Liechti, M. E. (2021). Acute subjective effects in LSD- and MDMA-assisted psychotherapy. Journal of Psychopharmacology, 35(4), 362–374. https://doi.org/10.1177/0269881120959604
88. Sessa, B., Higbed, L., O’Brien, S., Durant, C., Sakal, C., Titheradge, D., Brew-Girard, E., & Nutt, D. (2021). First study of safety and tolerability of MDMA-assisted psychotherapy in patients with alcohol use disorder. Journal of Psychopharmacology, 35(4), 375–383. https://doi.org/10.1177/0269881120965915
89. Sewell, R. A., Halpern, J. H., & Pope, H. G. (2006). Response of cluster headache to psilocybin and LSD. Neurology, 66(12), 1920–1922. https://doi.org/10.1212/01.wnl.0000219761.05466.43
90. Smith, K. W., Sicignano, D. J., Hernandez, A. V., & White, C. M. (2022). MDMA-assisted psychotherapy for treatment of post-traumatic stress disorder: A systematic review with meta-analysis. Journal of Clinical Pharmacology, 62(4), 463–471. https://doi.org/10.1002/jcph.1995
91. Stevens, J. (1987). Storming heaven: LSD and the American dream. Atlantic Monthly Press.
92. Strassman, R. J. (1996). Human psychopharmacology of N,N-dimethyltryptamine. Journal of Psychoactive Drugs, 28(1), 28–38. https://doi.org/10.1080/02791072.1996.10471714
93. Thomas, G., Lucas, P., Capler, N. R., Tupper, K. W., & Martin, G. (2013). Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. Current Drug Abuse Reviews, 6(1), 30–42. https://doi.org/10.2174/15733998113099990003
94. Timmermann, C., Roseman, L., Schartner, M., Milliere, R., Williams, L. T. J., Erritzoe, D., Muthukumaraswamy, S., Ashton, M., Bendrioua, A., Kaur, O., & Carhart-Harris, R. L. (2019). Neural correlates of the DMT experience assessed with multivariate EEG. Scientific Reports, 9(1), 16324. https://doi.org/10.1038/s41598-019-51974-4
95. Vamvakopoulou, I. A., Narine, K. A. D., Campbell, I., & Dyck, E. (2023). Mescaline: The forgotten psychedelic. Neuropharmacology, 224, 109356. https://doi.org/10.1016/j.neuropharm.2022.109356
96. Vizeli, P., Straumann, I., Holze, F., Schmid, Y., Dolder, P. C., & Liechti, M. E. (2022). Genetic polymorphisms of the serotonin transporter and adverse effects of MDMA. Frontiers in Pharmacology, 13, 854909. https://doi.org/10.3389/fphar.2022.854909
97. Wolfson, P. E., Andries, J., Feduccia, A. A., Jerome, L., Wang, J. B., Williams, E., Carlin, S. C., Sola, E., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2020). MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: A randomized pilot study. Scientific Reports, 10(1), 18065. https://doi.org/10.1038/s41598-020-75706-1
98. Yaden, D. B., Nayak, S. M., Gukasyan, N., Anderson, B. T., & Griffiths, R. R. (2022). The potential of psychedelics for end of life and palliative care. Current Topics in Behavioral Neurosciences, 56, 169–184. https://doi.org/10.1007/7854_2021_278
99. Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., & Gould, T. D. (2020). Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Psychopharmacology, 237(3), 841–853. https://doi.org/10.1007/s00213-019-05417-7
100. Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63(8), 856–864. https://doi.org/10.1001/archpsyc.63.8.856